There is reason to invest in TELK, compared to the market capitalization of its peers, TELK is substantially under priced.
Patients with idiopathic chronic neutropenia [ICN] who did not respond to treatment with granulocyte colony stimulating factors (G‑CSF) all improved on treatment with Telintra tablets.
Telik will complete Phase III trials and Telintra will get approved for the treatment of Low to Intermediate-1 risk MDS.
The technical picture, despite the sell off after each sharp rally, has definitely improved.